Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Chronic Graft-versus-Host Disease  by Villanueva, Fernanda N. et al.
BRIEF ARTICLESFrom the
de Sa
en Re
y Leo
Financial d
Correspon
PhD,
Paseo
pesim
Received M
 2009 Am
1083-8791
doi:10.101Oral Beclomethasone Dipropionate for the Treatment
of Gastrointestinal Chronic Graft-versus-Host Disease
Fernanda N. Villanueva, Jose Antonio Perez-Simon, Fernando F. Silva,
Teresa T. Caballero-Velazquez, Fermin F. Sanchez-Guijo, Conzuelo C. Can˜izo,
Lourdes L. Vazquez, Dolores D. Caballero, Jesus F. San MiguelThe most common approach for the treatment of chronic graft-versus-host disease (cGVHD) has been the
long-term use of systemic steroids. Beclomethasone dipropionate (BDP) is a topically active corticosteroid
with relatively low absorption from the gastrointestinal mucosa. It has been successfully used to treat acute
GVHD (aGVHD), but its use in the cGVHD setting is far more limited. In the current study, BDP was admin-
istered to 33 patients who underwent allogeneic transplantation and had biopsy-proven gastrointestinal
cGVHD (GI cGVHD). Twenty-six patients with GI cGVHD received BDP as first-line and 7 as either second-
or third-line treatment. All patients received BDP together with a calcineurin inhibitor, except for 1 patient
whowas also receiving mycophenolate mofetil (MMF). BDPwas administered for a minimum of 16 weeks and
was tapered during 4 additional weeks. Of those patients receiving BDP as the first line of treatment,
22 (84.6%) achieved complete remission (CR) of GI cGVHD, 2 (7.7%) achieved a partial response (PR)
and 2 (7.7%) did not respond or progressed. Median time to response was 28 days. Nevertheless, only
7 (27%) patients had maintained the response at last follow-up, whereas 19 (73%) finally relapsed or pro-
gressed. Median time to relapse was 147 days after the end of BDP. In the case of the patients who received
BDP as a second- or third-line treatment, 3 (42.9%) achieved CR and 2 (28.6%) PR. For the whole series of
patients, 13 patients (39.4%) were not receiving immunosuppressive treatment at final follow-up. Only
4 patients developed cytomegalovirus (CMV) reactivation, which was successfully treated with antiviral
drugs. No fungal infection was observed during the treatment period. In conclusion, the current study shows
that BDP, in the absence of systemic steroids, is a highly effective initial therapeutic approach for GI cGVHD,
which helps to avoid complications related to systemic steroids.
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Chronic graft-versus-host disease (cGVHD) is
a major complication after allogeneic hematopoietic
stem cell transplantation (HSCT) [1]. Its incidence
has increased over the past few years because of the
older age of the patients, the use of peripheral bloodServicio de Hematologıa, Hospital Clınico Universitario
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6/j.bbmt.2009.05.018as a source of progenitor cells, and the use of alterna-
tive donors [2].
Gastrointestinal (GI) GVHD affects up to 60% of
patients after HSCT [3]. In the cGVHD setting, diag-
nostic features for theGI tract include esophageal web,
stricture, or concentric rings documented by
endoscopy or a barium contrast radiograph [4]. Symp-
toms of anorexia, nausea, vomiting, and diarrhea are
not considered diagnostic of cGVHD, but are common
symptoms in patients with the condition. Wasting
syndrome can be a manifestation of cGVHD, but is
often multifactorial and may result from decreased ca-
loric intake, poor absorption, increased resting energy
expenditures, and hypercatabolism, for example [5].
Intestinal involvement is usually more severe and diffi-
cult to treat compared with other target organs. In this
regard, the Karnofsky score, presence of chronic diar-
rhea, weight loss, and skin involvement, allowed 3 sub-
groups of patients to be distinguished with respect to1331
Table 1. Patients and Transplant Characteristics
Patient characteristics (N 5 33)
Age
median (range) 33 (18-56)
CD34 cell dose
median (range) 5.35 (1-6.26)
Diagnosis:
AML 11
ALL 3
CML 2
CLL 3
MDS 4
NHL 6
HD 1
MM 2
Others 1
Disease status at transplant
First CR 15
$2nd CR 5
Chronic phase 2
Partial response 6
Refractory/progressive disease 2
Untreated 2
Others 1
Sex
Male/female 20 / 13
Type of donor
Related 21
Unrelated 11
Cord blood 1
Conditioning
Myeloablative 10
Reduced intensity 23
GVHD prophylaxis
CsA plus MTX 25
ATG or CAMPATH 4
CsA plus MMF 4
1332 Biol Blood Marrow Transplant 15:1331-1336, 2009F. N. Villanueva et al.different survival in an International Bone andMarrow
Transplant Research (IBMTR) study [6].
The most common approach for the treatment of
cGVHD has been the use of prednisone. When used
as a single agent, 3-year survival reported among
high-risk patients [7], identified as those with extensive
cGVHD plus thrombocytopenia, reached 26%. In this
subset of patients, the addition of cyclosporine A (CsA)
increased survival to 52% [8]. By contrast, the combi-
nation therapy did not improve the results of predni-
sone as a single agent among patients undergoing
bone marrow transplantation (BMT) who developed
standard-risk cGVHD [9]. The risks of this prolonged
immunosuppression include viral and fungal infec-
tions, hypothalamic-pituitary-adrenal (HPA) axis
suppression,myopathy, glucose intolerance, neuropsy-
chiatric disease, and bone demineralization [10].
Beclomethasone dipropionate (BDP) is a topically
active corticosteroid with relatively low absorption
from the GI mucosa into systemic circulation com-
pared with oral prednisone. BDP is metabolized in
the intestinal mucosa and the liver. The active metabo-
lite, 17-BMP, has an approximately 25-fold greater
glucocorticoid-receptor binding activity than BDP
[11,12]. In fact, BDP does not appear in the systemic
circulation because of its metabolism in the intestinal
mucosa and the liver, although 17-BMP can be de-
tected in the blood stream [13,14]. Accordingly, ad-
verse systemic effects are limited by incomplete
absorption and intestinal hydrolysis of the propionate
residues and by rapid clearance from the circulation
[14,15]. Oral BDP has demonstrated activity in GI
acute GVHD (aGVHD) [16,17] either alone [18] or
in combination with prednisone at 1 mg/kg. In this
patient population, BDP reduced the exposure to sys-
temic corticosteroids, was associated with fewer infec-
tions and, possibly, preserved graft-versus-tumor
(GVT) effects, yielding a statistically significant im-
provement in survival in a randomized, multicenter
clinical trial [19].
Despite thedeleterious effect of long-termexposure
to systemic steroids in the cGVHD setting, the infor-
mation available in the literature on the effectiveness
of BDP in gastrointestinal cGVHD is limited to 13 pa-
tients. In this series of patients, BDP was shown to be
safe and effective, although multiple courses might
have been necessary to achieve or maintain response
in some patients [20]. In the present report we describe
the safety and efficacy of BDP as a treatment in a series
of patients diagnosed with GI cGVHD.AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; CML, chronic myelogenous leukemia; CLL, chronic lympho-
cytic leukemia; MDS, myelodysplastic syndromes; NHL, nonHodgkin
lymphoma, HD, Hodgkin disease; MM, multiple myeloma; CR,
complete remission; GVHD, graft-versus-host disease; ATG, antithymo-
cyte globulin; CsA, cyclosporine; MMF, mycophenolate motefil; MTX,
methotrexate.
The infectious prophylaxis consisted of Trimethoprim-Sulfamethoxazole
and Acyclovir.MATERIALS AND METHODS
Patient Characteristics
BDP was administered to 33 patients who
underwent allogeneic peripheral blood stem celltransplantation (PBSCT) and had biopsy-proven GI
GVHD and clinical symptoms of cGVHD that devel-
oped after 100 days following transplantation. Patients
were able to swallow medication and had confirmed
negative stool cultures. Patient characteristics are sum-
marized in Table 1.
Patients were classified according to National
Institutes of Health (NIH) consensus criteria [21].
Diagnostic criteria were based on the clinical features,
although confirmatory biopsies were available for all
patients evaluated. No patient had esophageal involve-
ment.
Twenty-six patients with GI cGVHD received
BDP as first-line and 7 as either second- or third-line
treatment. As before, symptoms consisted of nausea/
vomiting in 13 patients, diarrhea in 12, anorexia and/
or malabsorption plus weight loss in 9, and abdominal
pain in 6 patients. As shown inTable 2, skin ormucosal
involvement was also observed and, for these patients,
Table 2. Organ Involvement at the Time of BDP Treatment
Patients: N (%)
Organ involvement among patients receiving BDP
as first-line treatment
Skin
Mild 6%
Moderate 1%
Oral mucosa
Mild 11%
Eyes
Mild 3%
Moderate 1%
Gut
Mild 22%
Moderate 4%
Gastrointestinal symptoms
Nausea/vomiting 13%
Diarrhea 12%
Anorexia/malabsortion/weight loss 9%
Abdominal pain 6%
Liver
Mild 5%
Organ involvement among patients receiving BDP
as greater than first-line treatment
Skin
Biol Blood Marrow Transplant 15:1331-1336, 2009 1333Beclomethasone Treatment for GI cGVHDa topical treatment was administered. In addition, 9
patients had liver function test abnormalities without
biopsy-proven GVHD, for whom ursodeoxycholic
acid was administered. Patients receiving BDP as
second- or third-line therapy had already received
systemic steroids.
BDP Treatment and Response Assessment
BDP was prepared as an emulsion of 250 mg of
BDP in 500 mL olive oil. It was administered at
a dose of 4 mL (2 mg) every 6 hours for a minimum
of 16 weeks, with tapering during 4 additional weeks.
Disease response was assessed at 4, 10, and 20weeks af-
ter the beginning of the treatment. cGVHD response
was assessed as recommended by the NIH Consensus
Development Project [21]: no response or progression
was defined as .25% worsening of cGVHD, partial
response was defined as .50% improvement, and
complete remission (CR) was recognized as the resolu-
tion of all signs and symptoms. Relapse was defined as
recurrence of symptoms after a CR once treatment had
been stopped.
Statistical Analysis
Events analyzed were calculated from the time of
transplantation using Kaplan-Meier product-limit
estimates. Treatment-realated mortality (TRM) was
defined as death because of causes unrelated to the
underlying disease and relapsing patients were cen-
sored at the time of relapse. GVHD-related mortality
was defined as death because of causes directly related
to GVHD, and deaths attributed to immunosuppres-
sion in patients requiring treatment for GVHD were
also considered as GVHD-related mortality. Overall
survival (OS) was calculated from transplantation until
death from any cause, and surviving patients were cen-
sored at last follow-up. The day of cGVHDwas calcu-
lated from transplantation to a diagnosis of cGVHD.
For statistical analyses, SPSS 10.0 (SPSS Inc, Chicago,
IL) was used. Differences were considered to be statis-
tically significant for values of P\ .05.Mild 3%
Moderate 1%
Severe 1%
Oral mucosa
Mild 7%
Eyes
Mild 7%
Moderate 1%
Gut
Mild 7%
Moderate 3%
Severe 1%
Gastrointestinal symptoms
Nausea/vomiting 7%
Diarrhea 4%
Anorexia/malabsorption/weight loss 7%
Abdominal pain 4%
Liver
Mild 4%
BDP indicates beclomethasone dipropionate.RESULTS
Of the 33 patients included in the study, cGVHD
flared at a median of 157 days (range: 95-1145 days).
All patients were considered as having extensive
cGVHD. Twenty-three patients had de novo, 6
patients had quiescent, and 4 progressive onset types
of cGVHD.
Five patients were considered as having an overlap-
ping syndrome. The degree of severity according to
the NIH scale was mild in 12 patients, moderate in
17 patients, and severe in 4 patients. Patients with
moderate or severe cGVHD received BDP because
of a high risk of relapse, considered as either activedisease including minimal residual disease (MRD) or
mixed chimerism at the time of treatment (n 5 14),
prior history of fungal infection (n 5 1), hepatitis B
virus (HBV) reactivation at the time of treatment
(n 5 1), prior history of steroid-related toxicity (n 5
2) or as the preference of the attending physician
(n 5 3). Twenty-six patients received BDP as a first-
line treatment, 3 patients as a second-line, and 4 pa-
tients as a third-line treatment. All patients received
BDP in conjunction with a calcineurin inhibitor plus
topical treatment on the skin, oral mucosa, or eyes
when required, except for 1 patient who was also re-
ceiving mycophenolate mofetil (MMF). Organ in-
volvement is specified in Table 2.
Of those patients receiving BDP as first-line treat-
ment 22 (84.6%) achieved CR of the GI cGVHD,
2 (7.7%) achieved a partial response (PR), and
2 (7.7%) did not respond or progressed. Median time
to response was 28 days (range: 7-137 days). Neverthe-
less, only 7 (27%) patients maintained the response at
2920,002555,002190,001825,001460,001095,00730,00365,000,00
1,0
0,8
0,6
0,4
0,2
0,0
Days after transplantation
Overal survival
Event free survival
78
55
Figure 1. Overall and event free survival.
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progressed. Median time to relapse was 147 days after
the end of BDP (range: 35-736 days). At the time of
relapse 2 patients were categorized as having limited
and 17 extensive cGVHD.
In the case of the patients who received BDP as
a second- or third-line treatment, 3 (42.9%) obtained
CR and 2 (28.6%) PR, whereas 2 patients (28.6%)
did not respond or progressed. Median time to
response was 45 days (range: 11-107 days). All patients
eventually relapsed at a median time of 231 days after
the end of BDP (range: 11-311 days). At the time of re-
lapse, 1 patient was considered to have limited and 6
had extensive cGVHD. At the time of relapse, 4 had
moderate and 3 had severe cGVHD. Of the entire se-
ries of patients 13 (39.4%) were not receiving immu-
nosuppressive treatment.
No differences in response were found between the
use of tacrolimus or CsA in combination with BDP.
Among patients who relapsed after first-line treat-
ment, 7 patients received BDP plus calcineurin inhib-
itor and 3 received BDP as a single agent. In the first
group, 6 patients achieved a CR in the gut and 1 could
not be evaluated, whereas in the latter group, 2
achieved a CR and 1 a PR.
No significant differences in response were
observed upon comparing patients categorized as hav-
ing mild or moderate cGVHD. Thus, 83% of patients
with mild compared with 76% of those with moderate
cGVHD achieved complete remission (P 5 .39).Toxicity and Outcome
With respect to treatment-related toxicity, 2 of the
33 patients included in the study developed Cushing-
like syndrome, 1 patient developed hyperglycemia, 2
patients developed musculoskeletal pain associated
with the BDP taper, and 1 patient developed nausea
that was probably related to the drug. During the treat-
ment period, only 4 patients developed CMV reactiva-
tion, which was successfully treated with antiviral
drugs. No fungal infection was observed and galacto-
mannan assays were negative.
With a median follow-up of 950 days (range:
158-1554 days) OS and event-free survival (EFS)
were 78% and 55% at 5 years, respectively (Figure 1).DISCUSSION
Several studies have addressed the role of BDP in
treating aGVHD. In a randomized trial, the use of
BDP in combination with prednisone at 1 mg/kg
reduced GVHD treatment failures from 65% in the
placebo arm to 39% in the BDP group (P 5 .003).
During the 80-day study period, there was additional
evidence of clinical benefit in the BDP arm, largelyas a result of the decreased need for protracted predni-
sone dosing [14].
In our own experience [18], the use of BDP with-
out systemic steroids yielded a 77% response rate in
a series of 26 patients diagnosed with GI aGVHD,
with 65.5% of patients achieving CR. At final follow-
up, 50% of the 26 patients did not require systemic
steroids to treat GI aGVHD.
In the cGVHD setting, the use of drugs with topic
effect in target organs should be of great importance
for avoiding systemic exposure to steroids, which
remain the gold standard of care for these patients.
Indeed, many patients diagnosed with cGVHD finally
die, not because of cGVHD itself, but to infectious
complications secondary to the immunosuppressive
effect of drugs administered to control it [2,14,22].
Moreover, toxicity associated with long-term treat-
ment steroids, such as myopathy, osteoporosis, hyper-
glycemia, weight gain with the characteristic
redistribution of body fat, growth retardation in chil-
dren, psychiatric disorders, or avascular hip necrosis,
also hamper the quality of life of the patients. To com-
plicate its management further, many studies have
shown cGVHD to be a favorable prognostic factor in
terms of survival because of a powerful graft-versus-
leukemia (GVL) effect that contributes to the lower
relapse rate observed in patients who develop it
[23-25]. For this reason, immunosuppressive treat-
ment must be carefully administered, not only on the
basis of the severity of cGVHD, but also taking into
account the risk of relapse and the disease status at
the time of treatment [26]. Under these conditions, it
would be desirable to develop strategies that allow
cGVHD to be controlled, but avoid the long-term
exposure to steroids. BDP therefore represents an in-
teresting alternative.
Biol Blood Marrow Transplant 15:1331-1336, 2009 1335Beclomethasone Treatment for GI cGVHDOnly 1 study reported by Iyer et al. [20] has so far
evaluated the use of BDP in the GI cGVHD. In this
study, 13 patients with GI cGVHD and 2 with
aGVHDwere analyzed. All patients but 1 had received
methylprednisolone at 2 mg/kg/day as prior therapy
for GI cGVHD and had no symptom relief. Nine
(60%) patients responded to BDP as measured by im-
provement or complete resolution of symptoms and
the ability to taper steroids. There were 20% complete
and 40% partial responses.
In the current study, we observed 84.6% CRs and
7.7% PRs among patients receiving BDP as first-line
treatment, whereas these figures were 42.9% and
28.6%, respectively, among patients receiving it as
more than first-line treatment. Our results illustrate
the efficacy of BDP as a first-line treatment, with an
impressive 84.6% CRs in this subset of patients. For
those patients who received BDP as a second- or
third-line treatment, which is a population more sim-
ilar to the series previously reported [20], 42.9% of
the patients achieved CR. It is worth mentioning
that, unlike the patients analyzed by Iyer et al. [20],
who had no symptom relief after receiving 2 mg/kg/
day methylprednisolone, patients included in the cur-
rent study were already off systemic steroids at the time
of cGVHD relapse, thus representing a population
with a better prognosis.
Despite this high response rate, a high relapse rate
was observed in the current study. Nevertheless, most
relapses occurred after BDP discontinuation and, con-
sidering that standard therapy is usually maintained for
at least 9 months, the use of BDP for 16 weeks with an
additional 4 weeks of tapering could have been too
short a period to ensure the maintenance of responses.
Moreover, all patients in the current series had re-
ceived peripheral blood as a source of progenitor cells
and, according to previous studies, cGVHD relapses
occur at a high frequency in this subset of patients
[9,22]. In this context, Flowers et al. [27] reported a re-
lapse rate ranging from 61% to 84% among patients
diagnosed with GVHD after peripheral blood alloge-
neic transplantation. Despite the high rate of recur-
rence, in our series of patients, 39.4% of our patients
were finally free of immunosuppressive treatment.
In addition, our study documents a low toxicity
profile, with only 2 cases of Cushing’s syndrome, 1
case of hyperglycemia, and 2 cases of musculoskeletal
pain during the period of BDP taper, which suggests
some degree of absorption of the drug. Corticosteroid
activity studies evaluating treatment with BDP have
not revealed any important secondary effects related
to infectious disease, although partial HPA axis sup-
pression is possible [14,18]. Metabolites of BDP are
systemically bioavailable, resulting in decreased adre-
nal responsiveness during the period of drug exposure
[20,28]. Recent studies of long-term use of oral, topi-
cally active corticosteroids have demonstrated littleevidence of clinical adrenal insufficiency [20,29]. Nev-
ertheless, 3 published series [14,18,19] did not produce
any evidence of HPA axis suppression in patients with
oral BDP treatment for GI GVHD, and clinical re-
sponses to this treatment suggest that absorption is
not necessary for efficacy.
In conclusion, the current study shows that BDP,
in the absence of systemic steroids, is a highly effective
initial therapeutic approach for GI cGVHD. This
helps to avoid complications related to systemic ste-
roids, although the final duration of treatment remains
to be determined.ACKNOWLEDGMENTS
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